The patent assigned to Odyssey Thera, further protects assays utilizing fragments of inherently fluorescent proteins, and the use of the assays for screening of defined panels of proteins.
The strategy is applicable in any cell type and using a wide range of reporters and detection methods.
Odyssey said that the invention enables identification and validation of genes and proteins involved in any cellular process, and also provides assays to study the effects of drugs and gene expression or knockout on specific pathways.
Odyssey Thera president and CEO John Westwick said that this patent extends the reach of Odyssey Thera’s technology platform.
"The assays and their use in gene vs. library and library vs. library screening provide a powerful strategy for biotherapeutic identification and optimization, diagnostic and biomarker development, the discovery of genetic modifiers of animal and plant cell traits, and bioprocess engineering," Westwick said.